Proteon Therapeutics's - PRTO market analysis on 27th September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
24th September 2020	Management Inc. Opaleye	100,000	Open or private purchase	$16.87	$1,687,000.00
24th September 2020	Management Inc. Opaleye	200,000	Open or private purchase	$16.87	$3,374,000.00
22nd September 2020	Blaine Davis	1,481	Open or private purchase	$16.91	$25,037.79
18th September 2020	John Gordon Freund	400,000	Open or private sale	$12.00	$4,800,000.00
14th September 2020	Randall Marshall	474	Open or private sale	$20.00	$9,480.00
14th September 2020	Randall Marshall	2,080	Open or private sale	$19.26	$40,060.80
11th September 2020	John Gordon Freund	500,000	Open or private sale	$10.00	$5,000,000.00
10th September 2020	Randall Marshall	239	Open or private sale	$18.00	$4,302.00
9th September 2020	Randall Marshall	5,309	Open or private sale	$18.10	$96,092.90
9th September 2020	Management Inc. Opaleye	45,000	Open or private purchase	$3.47	$156,100.50

Proteon Therapeutics

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001.

Ticker: PRTO

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1359931

Employees: 17

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis